10-OR: In Women with Prior Gestational Diabetes Mellitus, the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Improves Glucose Tolerance Irrespective of Body Weight Loss after Five Years of Treatment, but Effects Are Lost after Wash-Out

• DOI: 10.2337/db21-10-or
• Publication Date: 2021-06-24T22:14:51Z
• Authors: EMILIE S. ANDERSEN; SIGNE FOGHSGAARD; LOUISE VEDTOFTE; MARIE H. PEDERSEN; JULIE FORMAN; ELISABETH R. MATH...; JENS SVARE; JENS J. HOLST; TINE D. CLAUSEN; PETER DAMM; FILIP K. KNOP; TINA VILSBØLL
• Keywords: 0301 basic medicine; 03 medical and health sciences; 0302 clinical medicine; 3. Good health

Women with prior gestational diabetes mellitus (pGDM) are at high risk of developing type 2 (T2D). We evaluated whether treatment the glucagon-like peptide-1 receptor agonist, liraglutide, for 5 years reduces T2D in these women. Overweight women pGDM were randomized to an active arm (treatment liraglutide 1.8 mg once-daily years) or a control (placebo 1 year and thereafter no treatment) (Table). At baseline, one five years, 4-hour 75 g-oral glucose tolerance test (OGTT) intravenous isoglycemic infusion (IIGI) was conducted. Liraglutide-treated completed both OGTT on drug after week wash-out. Glucose improved liraglutide-treated vs. placebo However, this effect not maintained one-week wash-out liraglutide. No significant difference observed body weight, fasting plasma (FPG) hemoglobin A1c (HbA1c) between groups treatment.In conclusion, treatment, showed FPG HbA1c but continued exert beneficial oral when drug. After lost.View largeDownload slideView slide DisclosureE. S. Andersen: None. P. Damm: Advisory Panel; Self; Novo Nordisk A/S, Other Relationship; A/S. F. K. Knop: MSD Corporation, Sanofi, Consultant; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly Company, Pharmacosmos, Zealand Pharma Research Support; Speaker’s Bureau; Bayer AG, T. Vilsbøll: Amgen Bristol-Myers Squibb Gilead Sciences, Diabetes, Merck Sharp & Dohme Corp., Mundipharma International, Nordisk, Sun Pharmaceutical Industries Ltd. Foghsgaard: L. Vedtofte: M. H. Pedersen: J. Forman: E. R. Mathiesen: Sanofi-Aventis. Svare: Holst: Antag Therapeutics, Bainan Biotech, Spouse/Partner; Synklino ApS. D. Clausen: